CBP Rulings
Index coverage and update dates
- Indexed
- 6,578 rulings
- NY rulings from
- Nov 2024
- Newest here
- Nov 12, 2026
- Newest on CBP
- Nov 13, 2026
- Customs Bulletin through
- Nov 18, 2026
- Last sync with CBP
- 1 hour ago
- NY N346304Mar 21, 2025
The tariff classification of Hydralazine Hydrochloride Injection USP in dosage form, from India
In your letter dated February 26, 2025, you requested a tariff classification ruling. Hydralazine Hydrochloride Injection, imported in 20 mg/mL, is an antihypertensive. It is indicated for a condition called severe essential hypertension, also known as primary or idiopathic hypertension. The applicable subheading for the Hydralazine Hydrochloride Injection in dosage form will be 3004.90.9219, Harmonized Tariff Schedule of the United States (HTSUS), which provides “Medicaments… consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses … or in forms...
Source: rulings.cbp.gov (CROSS). This index holds New York rulings issued since Nov 2024 and the Headquarters rulings they cite. It is not the full CROSS database of 222,467 rulings, and it does not hold every Headquarters ruling. New rulings usually appear here within a few days of CBP publishing them; a ruling published long after its number was assigned can take several weeks. Revoked, modified and proposed marks come from the weekly Customs Bulletin, where CBP publishes most such actions under 19 U.S.C. 1625(c), read here from the Nov 2024 issues onward, and from the subjects of indexed Headquarters rulings. A revocation is marked from the date it takes effect. The absence of a mark is not confirmation that a ruling is still in effect. A ruling letter is binding on CBP only for the particular transaction or issue it describes (19 CFR 177.9). Confirm the text and status on CROSS before relying on a ruling. Not legal advice.